Antimicrobial Activity of Ceragenins against Vancomycin-Susceptible and -Resistant Enterococcus spp.
Pharmaceuticals · 23.11.2023 · 16 (12) · 1643
DOI: 10.3390/ph16121643 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceuticals, online erschienen am 23.11.2023. Verfasst von Mayram Hacioglu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Microbiology, Faculty of Pharmacy, Istanbul University, Istanbul 34116, Turkey. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Health Institutes of Turkey (TUSEB), Health Institutes of Türkiye (TUSEB).
Abstract (Originalsprache)
Ceragenins (CSAs) are a new class of antimicrobial agents designed to mimic the activities of endogenous antimicrobial peptides. In this study, the antibacterial activities of various ceragenins (CSA-13, CSA-44, CSA-90, CSA-131, CSA-138, CSA-142, and CSA-192), linezolid, and daptomycin were assessed against 50 non-repeated Enterococcus spp. (17 of them vancomycin-resistant Enterococcus-VRE) isolated from various clinical specimens. Among the ceragenins evaluated, the MIC50 and MIC90 values of CSA-44 and CSA-192 were the lowest (2 and 4 μg/mL, respectively), and further studies were continued with these two ceragenins. Potential interactions between CSA-44 or CSA-192 and linezolid were tested and synergistic interactions were seen with the CSA-192-linezolid combination against three Enterococcus spp., one of them VRE. The effects of CSA-44 and CSA-192 on the MIC values of vancomycin were also investigated, and the largest MIC change was seen in the vancomycin-CSA-192 combination. The in vivo effects of CSA-44 and CSA-192 were evaluated in a Caenorhabditis elegans model system. Compared to no treatment, increased survival was observed with C. elegans when treated with ceragenins. In conclusion, CSA-44 and CSA-192 appear to be good candidates (alone or in combination) for the treatment of enterococcal infections, including those from VRE.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmaceutical Microbiology, Faculty of Pharmacy, Istanbul University, Istanbul 34116, Turkey.
- Department of Pharmaceutical Microbiology, Faculty of Pharmacy, Gazi University, Ankara 06330, Turkey.
- Medical Microbiology Laboratory, Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, University of Health Sciences Ankara, Ankara 06200, Turkey.
- Department of Chemistry and Biochemistry, Brigham Young University, Provo, UT 84602, USA.
ORCID-Profile: Fatima Nur Yilmaz, Ozlem Oyardi, Paul B Savage
Förderung
- Health Institutes of Turkey (TUSEB)
- Health Institutes of Türkiye (TUSEB)
Zitieren
APA
Hacioglu, M., Yilmaz, F. N., Oyardi, O., Bozkurt Guzel, C., Inan, N., Savage, P. B., & Dosler, S. (2023). Antimicrobial Activity of Ceragenins against Vancomycin-Susceptible and -Resistant Enterococcus spp. Pharmaceuticals, 16(12), 1643. https://doi.org/10.3390/ph16121643
Vancouver
Hacioglu M, Yilmaz FN, Oyardi O, Bozkurt Guzel C, Inan N, Savage PB, et al. Antimicrobial Activity of Ceragenins against Vancomycin-Susceptible and -Resistant Enterococcus spp. Pharmaceuticals. 2023;16(12):1643. doi:10.3390/ph16121643
BibTeX
@article{Hacioglu2023,
author = {Hacioglu, Mayram and Yilmaz, Fatima Nur and Oyardi, Ozlem and Bozkurt Guzel, Cagla and Inan, Nese and Savage, Paul B and Dosler, Sibel},
title = {Antimicrobial Activity of Ceragenins against Vancomycin-Susceptible and -Resistant Enterococcus spp},
journal = {Pharmaceuticals},
year = {2023},
volume = {16},
number = {12},
pages = {1643},
doi = {10.3390/ph16121643}
}
EUVIMED